Clinical Trial Update: Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

Open-label extension for RA patients from a dosing flexibility Phase 3 study has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• UCB Pharma

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2012-06-14